S100A11: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: S100A11P1

NCBI ID: G729659

S100A11P1

Other Name(s): S100A11 pseudogene 1 | S100A11P | S100 calcium binding protein A11 pseudogene 1 | S100A14

S100A11: A Potential Drug Target Or Biomarker for Various Diseases

S100A11P1, also known as S100A11 pseudogene 1, is a gene that has been identified as a potential drug target or biomarker for various diseases. The gene is located on chromosome 10q35 and encodes a protein known as S100A11, which is a protein that is expressed in many tissues throughout the body.

S100A11 has been shown to be involved in a number of different diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these diseases has led to the idea that it may be a useful target for drug development.

One of the reasons why S100A11 is considered a potential drug target is its involvement in the development of cancer. Many studies have shown that high levels of S100A11 are associated with an increased risk of cancer, both in humans and in animal models. Additionally, S100A11 has been shown to promote the growth of cancer cells, which may make it an attractive target for cancer treatments.

Another potential drug target for S100A11 is its role in neurodegenerative diseases. Many of these diseases, such as Alzheimer's and Parkinson's, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. S100A11 has been shown to be involved in the development and progression of these diseases, and may be a useful target for drugs that are designed to slow down or reverse the progression of these conditions.

In addition to its potential role in cancer and neurodegenerative diseases, S100A11 has also been shown to be involved in autoimmune disorders. Many of these disorders, such as rheumatoid arthritis and lupus, are characterized by the immune system attacking the body's own tissues. S100A11 has been shown to be involved in the development and progression of these disorders, and may be a useful target for drugs that are designed to treat them.

Overall, S100A11P1 is a gene that has the potential to be a drug target or biomarker for a variety of diseases. Its involvement in the development and progression of cancer, neurodegenerative diseases, and autoimmune disorders makes it an attractive target for drug development. Further research is needed to fully understand the role of S100A11 in these diseases and to develop effective treatments.

Protein Name: S100A11 Pseudogene 1

The "S100A11P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about S100A11P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets